

Review began 03/07/2025 Review ended 03/14/2025 Published 03/18/2025

#### © Copyright 2025

Alahmadi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

DOI: 10.7759/cureus.80782

# A Wolf in Sheep's Clothing: Pseudohypobicarbonatemia in a Patient With Multiple Myeloma

Ziad Alahmadi <sup>1</sup>, Zain Haq <sup>2</sup>, Ami Patel <sup>3</sup>, Joshua D. King <sup>3</sup>

- 1. Internal Medicine, Umm Al-Qura University, Makkah, SAU 2. Nephrology, Samaritan Health Services, Corvallis, USA
- 3. Nephrology, University of Maryland Medical Center, Baltimore, USA

Corresponding author: Ziad Alahmadi, ziad.a.alahmadi@gmail.com

### **Abstract**

There are multiple methods to measure serum bicarbonate level which is crucial for diagnosis and management of acid-base disturbances. The most common method is directly measuring the total serum carbon dioxide ( $CO_2$ ) concentration in a basic metabolic panel. Another method is by indirect calculation of the bicarbonate concentration via the Henderson-Hasselbalch equation using the measured pH and partial pressure of  $CO_2$  ( $pCO_2$ ) in plasma. Multiple confounders can cause discrepancies in the measured bicarbonate in each method, such as increased concentration of serum lipids or proteins, that can alter measurement assays, leading to spuriously low serum bicarbonate values. In our case, we present a patient with falsely low reported bicarbonate levels in the setting of increased paraproteins due to multiple myeloma.

Categories: Internal Medicine, Nephrology, Oncology

**Keywords:** acid-base disorders, errors in the laboratory processes, high anion gap metabolic acidosis, multiple myeloma, serum bicarbonate

### Introduction

A low bicarbonate level in the basic metabolic panel (BMP) can be used usually as an initial value to screen for acid-base abnormalities. While there are multiple methods to measure serum bicarbonate level which is crucial for the diagnosis and management of acid-base disturbances, the most common method is by directly measuring the total serum carbon dioxide ( $CO_2$ ) concentration in a BMP via measuring total  $CO_2$  in the

blood, as approximately 95% of total  $\mathrm{CO}_2$  in the blood is in  $\mathrm{HCO}_3^-$  form [1,2]. To measure the total  $\mathrm{CO}_2$ , there are multiple chemistry analyzers that can use either enzymatic/photometric or electrode-based assays for measurement [1,2]. In our institution, we use Vitros® 350 Chemistry Analyzer (Ortho Clinical Diagnostics, Raritan, New Jersey, USA), which measures bicarbonate via carboxylation of phosphoenolpyruvate with phosphoenolpyruvate carboxylase (PEPC) to form oxaloacetate and inorganic phosphate. Oxaloacetate then converts to malate via malate dehydrogenase, which will produce nicotinamide adenine dinucleotide (NAD) from reduced nicotinamide adenine dinucleotide (NADH) reduction. The concentration of  $\mathrm{CO}_2$  is then identified by measuring the absorbance of unreacted NADH by spectrophotometry as described in the manufacturer guide [3]. An alternative method to figure the HCO3 value is by indirect calculation of the bicarbonate concentration via the Henderson-Hasselbalch equation using the measured pH and partial pressure of  $\mathrm{CO}_2$  (pCO<sub>2</sub>) in plasma.

Monoclonal gammopathy has been reported to cause alteration in anion gap as it can act as a cation or anion based on the paraprotein charge [4,5]. In the literature, elevated IgG has been reported to be cations causing lower anion gap than expected while elevated IgA or free light chains will cause elevated anion gap as it will act as anions [5]. In our case, we present a patient with a falsely low reported bicarbonate level with a high anion gap in the setting of increased paraproteins due to multiple myeloma.

## **Case Presentation**

A 47-year-old male patient with a history of IgA lambda chain multiple myeloma, cast nephropathy with chronic kidney disease (CKD), and hypertension presented with hypoxia, requiring high-flow oxygen that was attributed to pneumonia and volume overload from significant hypertension. Although he had clinical improvement of his hypoxia with antibiotics, intravenous (IV) diuretics, and hypertension treatment, he was noted to have a significantly low total  $\rm CO_2$  level on the initial BMP ranging 8-11 mmol/L (normal: 21-30 mmol/L) with anion gap of 20-26 mmol/L. He was presumed to have a high anion gap metabolic acidosis from his acute CKD and was at first treated with an IV bicarbonate infusion with no significant change in reported  $\rm CO_2$  value. He had normal lactate and normal blood sugar, and no apparent contributing factor was detected in history or physical examination that would explain this acid-base disturbance.



A venous blood gas (VBG) was performed, which showed a pH of 7.36, pCO  $_2$  of 42 mmHg, and calculated bicarbonate of 22 mmol/L; a simultaneous metabolic panel showed CO $_2$  of 10 mmol/L and anion gap of 23. Lambda light chain was significantly elevated at 1788.97 mg/L and IgA level of 3804 mg/dL. The patient was started on chemotherapy (carfilzomib/dexamethasone/cyclophosphamide regimen), which led to the reduction of both lambda light chains and IgA levels to 812.98 mg/L and 2276 mg/dL, respectively, within one week of initiating treatment, which was reflective to improved accuracy of bicarbonate levels in BMP compared to VBG with the reduction of paraproteins (Table 1).

Test	Day 1 of MM treatment	Day 7 of MM treatment
HCO <sub>3</sub> from BMP	10 mmol/L	19 mmol/L
Anion gap from BMP	23	13
pH from VBG	7.35	7.41
CO <sub>2</sub> from VBG	42 mmHg	37 mmHg
HCO <sub>3</sub> from VBG	22 mmol/L	23 mmol/L
Lambda light chain	1788.97 mg/L	812.98 mg/L
IgA level	3804 mg/dL	2276 mg/dL

## TABLE 1: Impact of paraprotein reduction on anion gap and HCO3 measurement

HCO3: bicarbonate; BMP: basic metabolic panel; VBG: venous blood gas; CO2: carbon dioxide; IgA: immunoglobulin A; MM: multiple myeloma

## **Discussion**

The difference in this patient's bicarbonate level between VBG and chemistry panel was explained by increased paraproteins, which have resulted in artifactual errors in PEPC-based laboratory analysis of serum bicarbonate. Manufacturer guide mentions total protein above 11 g/dL can impact the accuracy of the enzymatic assay and in our case, total protein was 12.8 g/dL. Concomitantly, IgA contributed as an unmeasured anion to explain the high anion gap. Discrepancies between serum and whole blood bicarbonate have also been reported in the literature due to various reasons including elevated triglycerides [6], increased paraproteins interfering with enzymatic assay as in our case [7], and tourniquet-induced venous stasis causing  ${\rm CO}_2$  accumulation [8]. In our case, the patient's anion gap and accuracy of serum bicarbonate level measurement improved as their lambda light chain levels subsequently decreased. Additionally, IgA can act as an unmeasured anion contributing to a high anion gap, which was evident in our case, this has been a documented phenomenon in previous studies [9,10]. Our patient anion gap has markedly decreased with the reduction of IgA level, which supports the literature findings.

Laboratory analytical artifacts leading to discrepancies between direct and indirect measurements of  $HCO_3$  have been rarely reported but can lead to unwarranted interventions. The appreciation of the patient, collection, and analysis of specific factors is crucial for accurate interpretation to avoid misdiagnosis or overtreatment based on spurious laboratory findings [11].

## **Conclusions**

Interpretation of serum  ${\rm CO}_2$  is usually accurate; rarely, there are factors that can cause false readings including elevated paraproteins and triglycerides. An arterial or VBG bicarbonate value can guide you to detect pseudohypobicarbonatemia in the appropriate clinical setting.

## **Additional Information**

# **Author Contributions**

All authors have reviewed the final version to be published and agreed to be accountable for all aspects of the

Concept and design: Ziad Alahmadi, Joshua D. King, Ami Patel, Zain Haq

Acquisition, analysis, or interpretation of data: Ziad Alahmadi, Joshua D. King, Ami Patel, Zain Haq



Drafting of the manuscript: Ziad Alahmadi, Joshua D. King, Ami Patel

**Critical review of the manuscript for important intellectual content:** Ziad Alahmadi, Joshua D. King, Ami Patel, Zain Haq

Supervision: Joshua D. King, Ami Patel

#### **Disclosures**

**Human subjects:** Consent for treatment and open access publication was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

#### References

- Centor RM: Chapter 196: serum total carbon dioxide. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd Edition. Walker HK, Hall WD, Hurst JW (ed): Butterworths, Boston; 1990.
- Rifai N, Horvath AR, Wittwer C: Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Elsevier, 2018
- Clinical and Laboratory Standards Institute (CLSI): Interference Testing in Clinical Chemistry; Approved Guideline, Second Edition. Clinical and Laboratory Standards Institute, Wayne, PA; 2005.
- De Troyer A, Stolarczyk A, De Beyl DZ, Stryckmans P: Value of anion-gap determination in multiple myeloma. N Engl J Med. 1977, 296:858-60. 10.1056/NEJM197704142961507
- 5. Paladini G, Sala PG: Anion gap in multiple myeloma . Acta Haematol. 1979, 62:148-52. 10.1159/000207561
- 6. Stein H: Spuriously low serum bicarbonate levels in patients with hyperlipidemia: a report of 4 cases . Am J Kidney Dis. 2019, 73:131-3. 10.1053/j.ajkd.2018.04.016
- Ma L, Zhao Z, Racine-Brzostek SE, Yang HS: A rare case of persistent pseudohypobicarbonatemia arising from chemistry analyzer-specific interference. Clin Chim Acta. 2021, 519:308-10. 10.1016/j.cca.2021.05.025
- 8. Goldwasser P, Manjappa NG, Luhrs CA, Barth RH: Pseudohypobicarbonatemia caused by an endogenous assay interferent: a new entity. Am J Kidney Dis. 2011, 58:617-20. 10.1053/j.ajkd.2011.06.003
- van Hoeven KH, Joseph RE, Gaughan WJ, et al.: The anion gap and routine serum protein measurements in monoclonal gammopathies. Clin J Am Soc Nephrol. 2011, 6:2814-21. 10.2215/CJN.07380711
- Kraut JA, Madias NE: Serum anion gap: its uses and limitations in clinical medicine. Clin J Am Soc Nephrol. 2007. 2:162-74. 10.2215/CIN.03020906
- 11. Carlton H, Shipman KE: Pitfalls in the diagnosis and management of acid-base disorders in humans: a laboratory medicine perspective. J Clin Pathol. 2024, 77:772-8. 10.1136/jcp-2024-209423